<DOC>
	<DOC>NCT00111423</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of an additional 28 weeks of treatment with pegsunercept for subjects who have completed treatment in a previous double-blind study (20000201 or 20000198). In addition, this study will evaluate the efficacy and the feasibility of subject self-administration on an outpatient basis.</brief_summary>
	<brief_title>Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Subjects who have completed 24 weeks of doubleblind treatment in a previous protocol (20000201 or 20000198) Females of childbearing potential and males must practice adequate contraception, in the judgement of the investigator, during the course of the study The subject or legally acceptable representative must give informed consent for participation in the study before any study specific procedures are performed Greater than a 7day duration from the week 24 visit in the previous study to the first dose in this study Any medical disability or condition (e.g., evidence of clinically significant liver dysfunction, active infection requiring treatment with systemic antiinfective agents) that would interfere with the assessment of safety of the study material or would compromise the ability of the subject to provide adequate informed consent Concurrent treatment with an investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Rheumatoid Arthritis, Inflammation</keyword>
	<keyword>Pegsunercept, PEG sTNF-RI</keyword>
	<keyword>Autoimmune, Amgen</keyword>
	<keyword>Clinical Trials</keyword>
</DOC>